Adalat pp 57-71 | Cite as

Synopsis of the Most Important Biopharmaceutical Facts About Nifedipine/Adalat

  • P.-J. Schattenberg
Conference paper


Calcium Gluconate Acid Dimethyl Ester Isotonic Sodium Chloride Solution Positive Urine Drug Screen Pyridine Metabolite 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    BPI (ed) (1990) Rote Liste. Cantor, Aulendorf, FRGGoogle Scholar
  2. 2.
    Dyrszka H, Wahn B (1977) Klinisches Bild und Therapie einer Überdosis des Koronartherapeutikums Nifedipin (Adalat®). Inn Med 4(l):31–34Google Scholar
  3. 3.
    Schiffl H, Ziupa J, Schollmeyer P (1984) Clinical features and management of nifedipine overdosage in a patient with renal insufficiency. Clin Tox 22(4):387–395CrossRefGoogle Scholar
  4. 4.
    Hemngton DM, Insley BM, Weinmann GG (1986) Nifedipine overdose. Am J Med 81:344–346CrossRefGoogle Scholar
  5. 5.
    Wells TG, Graham CJ, Moss MM, Kearns GL (1990) Nifedipine poisoning in a child. Pediatrics 86(l):91–94PubMedGoogle Scholar
  6. 6.
    Whitebloom D, Fitzharris J (1988) Nifedipine overdose. Clin Cardiol 11:505–506PubMedCrossRefGoogle Scholar
  7. 7.
    Strubelt O (1989) Vergiftungen durch Verapamil und andere Calciumantagonisten. DMW 114:1623–1627CrossRefGoogle Scholar
  8. 8.
    Hruby K (1984) Nebenwirkungen und Intoxikationen durch Kalziumantagonisten. Wiener Med Wochenschr 82:22–23Google Scholar
  9. 9.
    Strubelt O, Diederich K-W (1986) Experimental investigations on the antidotal treatment of nifedipine ovedosage. Clin Toxicol 24(2):135–149CrossRefGoogle Scholar
  10. 10.
    Streifler J, Wittenberg C, Rosenfeld JB (1983) Effects of different single doses of nifedipine on blood pressure, renal function, plasma aldosterone and renin in hypertensive subjects. In: Kaltenbach M, Neufeld HN (eds) Fifth International Adalat Symposium. Excerpta Medica, Amsterdam, pp. 164–171Google Scholar
  11. 11.
    Higuchi S, Shiobara Y (1978) Quantitative determination of nifedipine in human plasma by selected monitoring. Biomed Mass Spectrom 5(3):220–223PubMedCrossRefGoogle Scholar
  12. 12.
    Rämsch K-D (Bayer AG) (1981) Zur Pharmakokinetik von Nifedipin. Schwerpunkt Med 4(4):55–61Google Scholar
  13. 13.
    Foster TS, Hamann SR, Richards VR, Bryant PJ, Graves DA, McAllister RG (1983) Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects. J Clin Pharmacol 23:161–170PubMedGoogle Scholar
  14. 14.
    Kleinbloesem CH, van Brummelen P, van de Linde JA, Voogd PJ, Breimer DD (1984) Nifedipine: Kinetics and dynamics in healthy subjects. Clin Pharmacol Ther 35(6):742–749PubMedCrossRefGoogle Scholar
  15. 15.
    Horster FA, Duhm B, Maul W, Medenwald H, Patzschke K, Wegner LA (Bayer AG) (1972) Klinische Untersuchungen zur Pharmakokinetik von radioaktiv markiertem 4-(2′-Nitro-phenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsäuredimetylester. Arzneimittelforschung (Drug Res.) 22(2):330–334Google Scholar
  16. 16.
    Penny WJ, Lewis MJ (1989) Nifedipine is excreted in human milk. Eur J Clin Pharmacol 36:427–428PubMedCrossRefGoogle Scholar
  17. 17.
    Rosenkranz H, Schlossmann J, Scholtan W. (1974) Die Bindung von 4-(2′-Nitrophenyl)-2,6-chmethyl-l,4-dihydropyridin-3,5-dicarbonsäuredimethylester (Nifedipine) sowie von anderen koronarwirksamen Stoffen an die Eiweißkörper des Serums. Arzneimittelforschung (Drug Res) 24(4):455–466Google Scholar
  18. 18.
    Kleinbloesem CH (1985) Nifedipine: clinical pharmacokinetics and haemodynamic effects. Pasmans, The Hague, The Netherlands, pp. 9–31Google Scholar
  19. 19.
    Guengerich FP, Peterson LA, Böcker RH (1988) Cytochrome P-450-catalyzed hydroxylation and carboxylic acid ester cleavage of hantzsch pyridine esters. J Biol Chem 263(17): 8176–8183PubMedGoogle Scholar
  20. 20.
    Spital A, Scandüng JD (1983) Nifedipine in continuous ambulatory peritoneal dialysis. Arch Intern Med 143:2025PubMedCrossRefGoogle Scholar
  21. 21.
    Kleinbloesem CH, van Harten J, Wilson JPH, van Brummelen, Danhof M, Breimer DD Nifedipine: Kinetics and haemodynamic effects in patients with liver cirrhosis after i. v. and oral administration. In: Kleinbloesem CH (ed) Nifedipine, clinical pharmacokinetics and haemodynamic effects. Pasmans, The Hague, The Netherlands, pp. 135–147Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1991

Authors and Affiliations

  • P.-J. Schattenberg
    • 1
  1. 1.Pharma Research CenterBayer AGWuppertalGermany

Personalised recommendations